The simultaneous targeted Inhibition of ISG15 and HMGCR disrupts cancer stemness through metabolic collapse and induces synthetic lethality in pancreatic ductal adenocarcinoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Precision oncology, a transformative paradigm in cancer therapeutics, leverages molecular profiling to design personalized interventions. Building on our prior discovery of ISG15’s role in pancreatic cancer stem cell (CSC) generation, we identified co-upregulation of ISG15 and HMGCR in pancreatic ductal adenocarcinoma (PDAC). Dual suppression of ISG15 and HMGCR triggered synthetic lethality, effectively eradicating CSCs and impairing tumor progression. To exploit this synergy, we engineered a hyaluronic acid-coated liposomal nanoplatform (LNP-Kd/Statin) for co-delivery of ISG15-targeting siRNA and HMGCR-inhibiting statins. Mechanistically, ISG15 directly interacts with HMGCR, and the knockdown of ISG15 stabilizes the HMGCR protein by inhibiting K48 ubiquitin-proteasomal degradation, a process that occurs independently of ISGylation, paradoxically elevating cholesterol levels to sustain cell survival while depleting metabolic intermediates, thereby inducing vulnerability. Sterolomics profiling confirmed this metabolic rewiring, linking cholesterol flux collapse to CSC elimination. Our findings not only elucidate a novel ISG15-HMGCR regulatory axis in PDAC pathogenesis but also establish a nanotechnology-enabled strategy to disrupt cancer stemness through metabolic targeting. This work advances the translational potential of synthetic lethality in precision oncology for aggressive malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sun et al. demonstrated a synthetic lethal interaction between ISG15 and statins by delivering hyaluronic acid-coated nanoparticle of ISG15-siRNA + atorvastatin in cell cultures”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Sun et al., 2025
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“interferon-stimulated gene 15 (ISG15) knockdown in pancreatic cancer stem cells (CSCs) by siRNA results in the stabilization of HMGCR, increasing the cell cholesterol, making ISG15 low CSCs more susceptible to the action of statin”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Sun et al., 2025
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“newer delivery platforms such as the DZ-SIM nanoconjugate (Ou et al., 2022) and hyaluronic acid-coated nanoparticles (Sun et al., 2025) are of particular interest, because they may help overcome these pharmacokinetic limitations”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Sun et al., 2025
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533 · cited 1×
“Pancreatic ductal adenocarcinoma (PDAC), ranking as the third leading cause of cancer-related deaths [27], remains a therapeutic enigma.”
Park, W., Chawla, A., & O’Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 1,882
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321 · cited 1×
“Pancreatic cancer (PC) remains one of the most lethal malignancies, with a five-year survival rate below 10% due to late diagnosis, aggressive progression, and therapy resistance [1–3].”
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V., Czito, B., Del Chiaro, M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0017 · Cited by 1,304
Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
Liposome composition in drug delivery design, synthesis, characterization, and clinical application
Large, D. E., Abdelmessih, R. G., Fink, E. A., & Auguste, D. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113851 · Cited by 877 · cited 1×
“…irinotecan and nab-paclitaxel have validated nanomedicine in PDACs [23–25], our HA-coated By co-delivering ISG15 -siRNA and statins, we achieve tumor-specific targeting via CD44 receptor-mediated uptake [35–37], bypassing the dense stromal barrier that plagues conventional therapies [38, 39].”
Stoffel, E. M., Brand, R. E., & Goggins, M. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.012 · Cited by 512
Finley, L. W. S. (2023) · Cell · doi:10.1016/j.cell.2023.01.038 · Cited by 322
Loh, J.-J., & Ma, S. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.04.004 · Cited by 314
Lam, S. M., Zhang, C., Wang, Z., Ni, Z., Zhang, S., Yang, S., Huang, X., Mo, L., Li, J., Lee, B., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00425-4 · Cited by 284 · cited 2×
“Sterolomic analysis was performed by LipidALL Technologies following established protocols [26].”
InfluentialSelf-citation
Research works printed but not linked: 1
- Park W, Chawla A, O’Reilly EM. Pancreatic Cancer: Rev JAMA. 2021;326(9):851–62.
Cited by
Tackling cancer stemness with nanotechnology in the era of precision medicine
Guo, S., Yao, S., Meng, L., Chen, C., Lu, Y. L., Lu, R., Zahid, K. R., Raza, U., Wu, Q., & Chen, W. (2026) · BMEMat · doi:10.1002/bmm2.70099 · Cited by 2
Yu, Z., Qing, H., Wang, T., Xing, Z., Hou, Y., Ma, Y., Wang, T., Chen, S., Shi, W., Qin, L., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-338277 · Cited by 2
“Indeed, elevated HMGCR activity has been reported to fuel membrane biogenesis and oncogenic signalling to support rapid tumour growth, 53 while ULK1-driven autophagy is well-established as a cytoprotective mechanism that enables KRAS-driven tumours to withstand metabolic starvation and cytotoxic…”
The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review
Pîntea, A.-I., Croitoru, A. E., Dinu-Pîrvu, C. E., & Dima, S. O. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1815366
“In that context, newer delivery platforms such as the DZ-SIM nanoconjugate (Ou et al., 2022) and hyaluronic acid-coated nanoparticles (Sun et al., 2025) are of particular interest, because they may help overcome these pharmacokinetic limitations.”
Metabolic Crosstalk Between Host and Tumor as a Circuit of Resilience in Cancer Therapy
Wang, J., Wu, H., Wang, T., & Nie, M. (2026) · Cells · doi:10.3390/cells15111008
Self-citationSun, H., Qu, C., Yang, C., Chen, J., Yue, N., Du, J., Gong, R., Yu, Q., Gao, C., Zhao, C., et al. (2026) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2026.06.003
Metadata
- Authors
- Sun, J., Wang, J.-M., Zhang, Q., Lin, W.-Y., Tang, L., Lu, S.-Y., Li, B.-Q., Du, Z.-X., & Wang, H.-Q.
- Affiliations
- Nanjing University of Chinese Medicine (CN)
- Criminal Investigation Police University of China (CN)
- First Hospital of China Medical University (CN)
- China Medical University (CN)
- Corresponding author
- Du, Zhen-Xian
- Wang, Hua-Qin
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-12-09
- Volume
- 44
- Issue
- 1
- Pages
- 317-317
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- PMC
- PMC12690959
- OpenAlex
- W4417230833
- Cited by
- 5
- References
- 36
- Citations by year
- 2026: 5
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82203337)
- Natural Science Foundation of Liaoning Province (2024-MSLH-542, 2023JH2/20200160)
- Applied Basic Research Program (2023JH2/101600012)
- Liaoning Province Central Guidance Local Science and Technology Development Fund Plan (2024JH6/100800018)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- ISG15, HMGCR, pancreatic ductal adenocarcinoma, cancer stem cells, synthetic lethality, cholesterol metabolism, K48-linked ubiquitination, protein stability, siRNA delivery, statins, metabolic targeting, precision oncology
- MeSH terms
- Synthetic Lethal Mutations, Animals, Humans, Hydroxymethylglutaryl CoA Reductases, Pancreatic Neoplasms, Neoplastic Stem Cells, Ubiquitins, Cytokines, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The simultaneous targeted Inhibition of ISG15 and HMGCR disrupts cancer stemness through metabolic collapse and induces synthetic lethality in pancreatic ductal adenocarcinoma. https://app.cochat.ai/papers/10.1186/s13046-025-03561-x
- The paper
- Sun, J., Wang, J.-M., Zhang, Q., Lin, W.-Y., Tang, L., Lu, S.-Y., Li, B.-Q., Du, Z.-X., & Wang, H.-Q. (2025). The simultaneous targeted Inhibition of ISG15 and HMGCR disrupts cancer stemness through metabolic collapse and induces synthetic lethality in pancreatic ductal adenocarcinoma. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-025-03561-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.